User profiles for MICKAEL GUEDJ

Mickaël Guedj

Head of Biometrics, Data & Decision Sciences | Nanobiotix
Verified email at servier.com
Cited by 8507

ChEBI: a database and ontology for chemical entities of biological interest

…, R Alcántara, M Darsow, M Guedj… - Nucleic acids …, 2007 - academic.oup.com
Chemical Entities of Biological Interest (ChEBI) is a freely available dictionary of molecular
entities focused on ‘small’ chemical compounds. The molecular entities in question are either …

A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis

…, B Schaëffer, S Le Crom, M Guedj… - Briefings in …, 2013 - academic.oup.com
During the last 3 years, a number of approaches for the normalization of RNA sequencing
data have emerged in the literature, differing both in the type of bias adjustment and in the …

[HTML][HTML] A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome

…, S Courtade-Gaiani, L Xuereb, M Guedj… - Nature …, 2021 - nature.com
There is currently no approved treatment for primary Sjögren’s syndrome, a disease that
primarily affects adult women. The difficulty in developing effective therapies is -in part- because …

Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population

P Dieude, M Guedj, J Wipff, B Ruiz… - Annals of the …, 2010 - ard.bmj.com
Background TNFAIP3 encodes the ubiquitin-modifying enzyme, a key regulator of
inflammatory signalling pathways. Convincing associations between TNFAIP3 variants and …

Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine

P Moingeon, M Kuenemann, M Guedj - Drug discovery today, 2022 - Elsevier
Artificial Intelligence (AI) relies upon a convergence of technologies with further synergies
with life science technologies to capture the value of massive multi-modal data in the form of …

Analysis of drug combinations: current methodological landscape

J Foucquier, M Guedj - Pharmacology research & perspectives, 2015 - Wiley Online Library
Combination therapies exploit the chances for better efficacy, decreased toxicity, and reduced
development of drug resistance and owing to these advantages, have become a standard …

[HTML][HTML] Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and …

…, KA Nave, MW Sereda, E Vial, M Guedj… - Orphanet journal of rare …, 2014 - Springer
Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common inherited sensory and
motor peripheral neuropathy. It is caused by PMP22 overexpression which leads to defects of …

[HTML][HTML] Should We Abandon the t-Test in the Analysis of Gene Expression Microarray Data: A Comparison of Variance Modeling Strategies

…, A De Reynies, L Marisa, C Paccard, G Nuel, M Guedj - PloS one, 2010 - journals.plos.org
High-throughput post-genomic studies are now routinely and promisingly investigated in
biological and biomedical research. The main statistical approach to select genes differentially …

[HTML][HTML] Comparative functional genomics revealed conservation and diversification of three enhancers of the isl1 gene for motor and sensory neuron-specific …

O Uemura, Y Okada, H Ando, M Guedj… - Developmental …, 2005 - Elsevier
Islet-1 (Isl1) is a member of the Isl1 family of LIM-homeodomain transcription factors (LIM-HD)
that is expressed in a defined subset of motor and sensory neurons during vertebrate …

[HTML][HTML] An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients …

…, C Scart-Grès, S Nabirotchkin, M Guedj… - Orphanet journal of rare …, 2014 - Springer
Background Charcot-Marie-Tooth type 1A disease (CMT1A) is a rare orphan inherited
neuropathy caused by an autosomal dominant duplication of a gene encoding for the structural …